Sofinnova Investments related stories
All articles and analysis
Juno shows life science startups can be unicorns, too: VCJLife science startups raise big rounds quickly, as cancer-fighting Juno collects $300 million in under a year.
Juno shows life science startups can be unicorns, tooLife science startups raise big rounds quickly, as cancer-fighting Juno collects $300 million in under a year
Big data analytics firm Guavus fetches $20 mlnGuavus has received $20 million in funding. The investors included Artiman Ventures, Sofinnova Ventures, Intel Capital, SingTel Innov8, Investor Growth Capital, QuestMark Partners and Goldman Sachs. Based in San Mateo, Calif., Guavus is a provider of big data analytics solutions for operational intelligence.
- Dermira fetches $51 mln Series C
Dermira, a Redwood City, Calif-based maker of medical dermatology products, has closed $51 million in Series C financing. The investors included Bay City Capital, New Enterprise Associates, Canaan Partners, UCB S.A., Apple Tree Partners, Aisling Capital, Rock Springs Capital and Sabby Capital. Leerink Partners was the placement agent for the financing. In addition to the funding, Dermira has named Andrew Guggenhime as chief operating officer and chief financial officer; Christine Conroy as senior vice president of regulatory affairs; and Christine Ring as vice president of legal. It has also appointed David E. Cohen, Matthew Fust, Mark McDade and William Ringo to its board of directors.
Year of the earSonitus and EarLens are leading the charge of venture-funded companies focused on the ear
Sofinnova Ventures beats Fund IX target with $500 mlnSofinnova Ventures has closed its ninth fund on its $500 million hard cap, beating its original target of $425 million, the firm announced.
Drug backer Sofinnova rounds up $500 mln for Fund IXThe late-stage life sciences investor reaches hard cap, exceeding its $425 million target
Sofinnova Ventures targets $425 mln for Fund IXSofinnova Ventures, which targets primarily investments in late-stage clinical drug development companies, is back in market targeting $425 million for Fund IX.
- Illinois TRS hikes PE allocation to 14 pct from 12 pct
The Teachers’ Retirement System of Illinois unveiled a new asset allocation mix on Wednesday, June 25, that raises its long-term target allocation to private equity from 12 percent to 14 percent.
- VC-backed Sorbent Therapeutics expands board of directors
Sorbent Therapeutics, a Sunnyvale, Calif.-based biopharmaceutical firm focused on treating cardiovascular and renal diseases, has added Jay Shepard and William D. Waddill to its board of directors. Shepard is an executive partner at Sofinnova Ventures while Waddill is the senior vice president and chief financial officer at Calithera Biosciences. Sorbent's backers include CMEA Capital, ARCH Venture Partners, Sofinnova Ventures, AgeChem and Novartis Venture Funds.